Multiple sclerosis, an inflammatory, demyelinating disease of the CNS curre
ntly lacks an effective therapy. We show here that CNS inflammation and cli
nical disease in experimental autoimmune encephalomyelitis, an experimental
model of multiple sclerosis, could be prevented completely by a replicatio
n-defective adenovirus vector expressing the anti-inflammatory cytokine IL-
10 (replication-deficient adenovirus expressing human IL-10), but only upon
inoculation into the CNS where local infection and high IL-10 levels were
achieved. High circulating levels of IL-10 produced by i.v. infection with
replication-deficient adenovirus expressing human IL-10 was ineffective, al
though the immunological pathways for disease are initiated in the peripher
y in this disease model. In addition to this protective activity, intracran
ial injection of replication-deficient adenovirus expressing human IL-10 to
mice with active disease blocked progression and accelerated disease remis
sion. In a relapsing-remitting disease model, IL-10 gene transfer during re
mission prevented subsequent relapses. These data help explain the varying
outcomes previously reported for systemic delivery of IL-10 in experimental
autoimmune encephalomyelitis and show that, for optimum therapeutic activi
ty, IL-10 must either actress the CNS from the peripheral circulation or be
delivered directly to it by strategies including the gene transfer describ
ed here.